Primary pulmonary hypertension

被引:458
作者
Runo, JR [1 ]
Loyd, JE [1 ]
机构
[1] Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA
关键词
D O I
10.1016/S0140-6736(03)13167-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary pulmonary hypertension (PPH) is a rare disorder characterised by raised pulmonary-artery pressure in the absence of secondary causes. Precapillary pulmonary arteries are affected by medial hypertrophy, intimal fibrosis, microthrombosis, and plexiform lesions. Most individuals present with dyspnoea or evidence of right heart failure. Echocardiography is the best non-invasive test to screen for suspected pulmonary hypertension. The discovery of mutations In the coding region of the gene for bone morphogenetic protein receptor 2 in patients with familial and sporadic PPH may help not only to elucidate pathogenesis but also to direct future treatment options. The pathogenesis is not completely understood, but recent investigations have revealed many possible candidate modifier genes. Without treatment, the disorder progresses in most cases to right heart failure and death. With current therapies such as epoprostenol, progression of disease is slowed, but not halted. Many promising new therapeutic options, including prostacyclin analogues, endothelin-l-receptor antagonists, and phosphodiesterase inhibitors, improve clinical function and haemodynamic measures and may prolong survival.
引用
收藏
页码:1533 / 1544
页数:12
相关论文
共 158 条
[1]   Appetite-suppressant drugs and the risk of primary pulmonary hypertension [J].
Abenhaim, L ;
Moride, Y ;
Brenot, F ;
Rich, S ;
Benichou, J ;
Kurz, X ;
Higenbottam, T ;
Oakley, C ;
Wouters, E ;
Aubier, M ;
Simonneau, G ;
Begaud, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) :609-616
[2]   Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension [J].
Aguilar, RV ;
Farber, HW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (05) :1846-1850
[3]   Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer [J].
Akiyama, Y ;
Iwanaga, R ;
Saitoh, K ;
Shiba, K ;
Ushio, K ;
Ikeda, E ;
Iwama, T ;
Nomizu, T ;
Yuasa, Y .
GASTROENTEROLOGY, 1997, 112 (01) :33-39
[4]  
Aris R, 1998, AM J RESP CRIT CARE, V158, P335
[5]   Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor [J].
Atkinson, C ;
Stewart, S ;
Upton, PD ;
Machado, R ;
Thomson, JR ;
Trembath, RC ;
Morrell, NW .
CIRCULATION, 2002, 105 (14) :1672-1678
[6]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+
[7]   INDICATIONS FOR AND RESULTS OF SINGLE, BILATERAL, AND HEART-LUNG TRANSPLANTATION FOR PULMONARY-HYPERTENSION [J].
BANDO, K ;
ARMITAGE, JM ;
PARADIS, IL ;
KEENAN, RJ ;
HARDESTY, RL ;
KONISHI, H ;
KOMATSU, K ;
STEIN, KL ;
SHAH, AN ;
BAHNSON, HT ;
GRIFFITH, BP .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1994, 108 (06) :1056-1065
[8]   Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension - Open-label pilot study [J].
Barst, RJ ;
Rich, S ;
Widlitz, A ;
Horn, EM ;
McLaughlin, V ;
McFarlin, J .
CHEST, 2002, 121 (06) :1860-1868
[9]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[10]   SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION WITH LONG-TERM CONTINUOUS INTRAVENOUS PROSTACYCLIN [J].
BARST, RJ ;
RUBIN, LJ ;
MCGOON, MD ;
CALDWELL, EJ ;
LONG, WA ;
LEVY, PS .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) :409-415